Literature DB >> 28614151

Success Rate of Variable Collar Size Frosted Jones Tubes.

C Blake Perry1, Roger A Dailey.   

Abstract

PURPOSE: To describe success rates and long-term outcomes of conjunctivodacryocystorhinostomy (CDCR) with larger collar (4.5 or 5.0 mm) frosted Jones tubes (FJTs).
METHODS: A retrospective chart review of all patients who received a larger collar (4.5 or 5.0 mm) FJT following CDCR by an author (RAD) was performed between January 1, 2010 and July 1, 2016. Patient demographics, etiology of tearing, follow-up time from placement of larger collar FJT, original tube collar diameter, number and sizes of collar adjustments, tearing status, and complications were recorded. Exclusion criteria included follow up less than 6 months after placement of a larger collar FJT. The study was IRB approved, HIPAA compliant, and adherent to the Declaration of Helsinki.
RESULTS: Twenty-five patients (29 eyes) met the inclusion criteria. Average follow-up time was 30 months. Twenty-eight out of 29 eyes had complete resolution of tearing after placement of larger collar FJT and no tubes were lost. Fourteen out of 29 eyes required adjustment in collar size after a larger collar was placed. Two out of 13 eyes that had a 5.0 mm collar placed required exchanged due to collar prominence.
CONCLUSION: With the use of larger collar FJTs, the long-term success of CDCR in tearing patients remains highly effective. This study demonstrates larger collar FJTs are well tolerated and help reduce the chance of tube loss.

Entities:  

Mesh:

Year:  2018        PMID: 28614151     DOI: 10.1097/IOP.0000000000000942

Source DB:  PubMed          Journal:  Ophthalmic Plast Reconstr Surg        ISSN: 0740-9303            Impact factor:   1.746


  1 in total

1.  Endoscopy-guided diode laser-assisted transcaruncular StopLoss Jones tube implantation for canalicular obstructions in primary surgery.

Authors:  Yongwei Guo; Alexander C Rokohl; Katharina Kroth; Senmao Li; Ming Lin; Renbing Jia; Ludwig M Heindl
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2020-10-06       Impact factor: 3.117

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.